NZ624250A - 18f-fluciclovine compositions in citrate buffers - Google Patents

Abstract

Disclosed herein are pharmaceutical compositions comprising [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid ([18F]FACBC, commonly known as [18F]-Fluciclovine), and a 50-100 mM citrate buffer and having a pH between 4 and 5 which provides for decreased radiolysis, and not more than 150 µg/mL 1-amino-3-hydroxyl-cyclobutane-1-carboxylic acid (hydroxyl-ACBC). Also disclosed is a method to obtain said pharmaceutical composition.

Description

F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS Technical Field of the Invention The present invention s to a drug product composition and in ular to a composition comprising a positron emission tomography (PET) . The composition of the present invention has certain advantages over prior art formulations.

Description of Related Art The non-natural amino acid [18 F]aminofluorocyclobutanecarboxylic acid ([ 18 F]FACBC, also known as [18 F]-Fluciclovine) is taken up specifically by amino acid transporters and has shown promise for tumour imaging with positron emission tomography (PET).

In radioactive diagnostic g agents, a problem often arises such that compounds ose by self-radiation during delivery of the agents so as to cause decrease in radiochemical purity due to so-called radiolysis. In PET tracers sing nuclides such as 11 C and 18 F, radiolysis often becomes more problematic since the half-life of the nuclides used therein is relatively short, e.g. as compared with nuclides used in single photon emission tomography (SPECT) such as 99m Tc, and thus radioactivity upon shipment must be set larger than SPECT agents, thereby making the resulting radiation energy thereof higher.

Various methods for inhibiting radiolysis in PET tracers have been examined. For example in compositions comprising [18 F]-fluorodeoxyglucose ([18 . WO 2003/090789 discloses a method of reducing the radiolysis of [18 F]FDG by adding a weak acid-based buffer to an [18 F]FDG solution. WO 43497 discloses adding ethanol to a [18 F]FDG on to obtain a composition of [18 F]-FDG having ed stability.

In the case of [18 F]FACBC different strategies have been adopted. EP 2106808 (A1) discloses that for a composition comprising [18 F]FACBC, when the pH value is not more than 5.9, stability thereof is maintained even if there exist no pharmaceutical additives or buffers that prevent radiolysis.

EP 2080526 (A1) ses that radiolysis can be inhibited by adding a sugar lactone such as ascorbic acid and glucono-o-lactone to [18 F]FACBC. An exemplary ition taught by EP 2080526 (A1) has a radioactivity of 1.4GBq in about 2 mL and contains the sugar lactone in a proportion of 10mmol/mL immediately after production providing a radioactivity of 50 to 225 MBq when the agent is used, sufficient for PET imaging in adults. It was also disclosed that ascorbic acid at concentrations of 0.5-10.0 µmol/mL can inhibit decomposition of [18 F]FACBC solution. In this case, radiolysis was inhibited at a tration of 700 MBq/mL at maximum.

EP 8 (A1) discloses a method to prepare a stabilised formulation of [18 F]FACBC comprising diluting a solution of [18 F]FACBC and then adding an acid in an amount sufficient to adjust the pH of the solution to 2.0-5.9. Suitable acids disclosed are ascorbic acid, benzoic acid, hydrochloric acid, acetic acid, citric acid, gentisic acid, and oxalic acid, with hydrochloric acid preferred. EP 8 (A1) also discloses that a sugar alcohol such as erythritol xylitol, sorbitol or mannitol can be added as a further additive to inhibit radiolysis and e stability.

In these known [18 C compositions radiostability is maintained by adjusting pH within a relatively wide range using an acid and/or including a suitable additive.

Adjustment of pH using an acid rather than using a buffer has the advantage that the ionic strength of the ition is lower.

In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the ion. Unless specifically stated otherwise, reference to such external documents is not to be ued as an admission that such documents, or such sources of information, in any iction, are prior art, or form part of the common general knowledge in the art.

In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application Summary of the Invention The present ion provides a pharmaceutical composition of [18F]amino fluorocyclobutanecarboxylic acid (18F-FACBC) wherein said composition comprises: (i) 50-100 mM citrate buffer; (ii) has a pH of 4.0-5.0; and (iii) not more than 150 µg/mL 1-aminohydroxyl-cyclobutanecarboxylic acid (hydroxyl-ACBC).

The invention also relates to a method to obtain a harmaceutial composition wherein said composition is as defined above and wherein said method comprises: (i) reacting with a suitable source of [18F]fluoride a precursor compound of Formula I: LG is a leaving group; PG1 is a carboxy protecting group; and, PG2 is an amine protecting group; to obtain a compound of Formula II: (II) wherein PG1 and PG2 are as d for Formula II; (ii) ng said compound of Formula II with a PG1 deprotecting agent to obtain a compound of Formula III: (III); wherein PG2 is as defined for Formula I; (iii) reacting said compound of Formula III with a PG 2 ecting agent to obtain [18F]FACBC; (iv) formulating said [18F]FACBC with e buffer to obtain said pharmaceutical ition.

The invention also provides a radiopharmaceutical composition when ed by a method of the invention.

Brief Description of the Invention The present invention provides a pharmaceutical composition comprising ACBC having certain advantages over known compositions comprising [18F]FACBC. Also provided by the present invention is a method to obtain the composition of the invention. The composition of the present invention is resistant to degradation, can be autoclaved or diluted in saline (i.e. 0.9 % NaCl), and still maintain its pH in a narrow range. Furthermore, the pharmaceutical composition of the present invention does not require any radiostabiliser in order to maintain good tability over its shelf-life.

Detailed Description of the Invention Described is a pharmaceutical composition of 18F-FACBC characterised in that said composition: (i) comprises 50-100 mM e buffer; and, (ii) has a pH of 4.0-5.0.

The term "pharmaceutical composition" refers to a composition comprising a pharmaceutical together with a biocompatible carrier in a form suitable for mammalian administration. A "biocompatible carrier" is a fluid, especially a liquid, in which a pharmaceutical is suspended or dissolved, such that the composition is physiologically tolerable, i.e. can be administered to the mammalian body t toxicity or undue fort. The biocompatible carrier is suitably an injectable carrier liquid such as sterile, n-free water for ion or an aqueous solution such as saline.

The ceutical composition of the invention preferably comprises 60-90 mM citrate buffer, most preferably 75-85 mM citrate buffer.

The pharmaceutical composition of the invention preferably has a pH of 4.1-4.5, most preferably 4.3-4.4.

The pharmaceutical composition of the invention preferably has an end of synthesis (EOS) radioactive concentration (RAC) of at least 1000 MBq/mL, alternatively at least 1500 MBq/ml.

The term "end of synthesis" refers to the point in time when the ed compound is collected in the product collection vial.

The pharmaceutical composition of the present invention has a favourable impurity profile, with the main non-radioactive impurities being 1-aminohydroxyl-cyclobutane carboxylic acid (hydroxyl-ACBC), 1-aminofluoro-cyclobutanecarboxylic acid (FACBC) and ochloro-cyclobutanecarboxylic acid (chloro-ACBC).

In the composition of the invention there is not more than 150 µg/mL yl-ACBC, most preferably not more than 80 µg/mL hydroxyl-ACBC.

It is preferred that there is not more than 0.15 µg/mL FACBC, most ably not more than 0.10 µg/mL FACBC.

It is preferred that there is not more than 2.0 µg/mL chloro-ACBC, most preferably not more than 1.0 µg/mL chloro-ACBC.

The term "not more than" should be understood to mean any amount less than the quoted quantity. Therefore not more than 100 µg/mL means any amount between 0-100 µg/mL, and in an ideal embodiment of the composition of the present invention there would be zero µg/mL of each ty present in the composition of the invention.

However, in reality, zero µg/mL of an impurity might not be achievable and it is more likely that at least a trace amount of the impurity remains in the composition, i.e. in the case of hydroxyl-ACBC the term not more than 150 µg/mL covers e.g. 50-150 µg/mL, not more than 0.10 µg/mL for FACBC covers e.g. 0.05-0.10 µg/mL, and not more than 1.0 µg/mL chloro-ACBC covers e.g. 0.25-1.0 µg/mL.

An advantage of the composition of the present invention is that the pH, stability and impurity profile can be kept within a very narrow range over a long shelf-life, at high activities, and when lated e.g. by autoclaving or by dilution with 0.9% saline.

In a preferred embodiment, the pharmaceutical composition of the invention does not se a radiostabiliser. It is common for pharmaceutical compositions sing radioactive pharmaceuticals to include a radiostabiliser. For example, known pharmaceutical compositions of [18F]FACBC include a sugar alcohol or a sugar lactone.

EP 2080526 (A1) discloses that radiolysis can be inhibited by adding a sugar e such as ascorbic acid and glucono-o-lactone to [18F]FACBC, and EP 2119458 (A1) discloses that a sugar alcohol such as erythritol xylitol, sorbitol or mannitol can be added as an additive to inhibit radiolysis and improve stability. No such radiostabiliser is required in the harmaceutical composition of the present invention in order to maintain a life of up to around 10 hours.

In another aspect the present invention provides a method to obtain a radiopharmaceutial composition wherein said composition is as defined hereinabove, and wherein said method comprises: (i) ng with a suitable source of [18F]fluoride a precursor compound of Formula I: wherein: LG is a leaving group; PG1 is a carboxy protecting group; and, PG2 is an amine protecting group; to obtain a compound of Formula II: (II) wherein PG1 and PG2 are as defined for Formula II; (ii) reacting said compound of Formula II with a PG1 deprotecting agent to obtain a compound of Formula III: (III); wherein PG2 is as defined for Formula I; (iii) reacting said nd of Formula III with a PG 2 deprotecting agent to obtain [18F]FACBC; (iv) formulating said [18F]FACBC with citrate buffer to obtain said pharmaceutical composition.

The "source of [18F]fluoride" suitable for use in the invention is ly obtained as an aqueous solution from the nuclear reaction n)18F. In order to se the reactivity of fluoride and to reduce or minimise hydroxylated by-products resulting from the presence of water, water is typically removed from [18F]-fluoride prior to the reaction, and fluorination reactions are carried out using anhydrous reaction ts (Aigbirhio et al 1995 J Fluor Chem; 70: 279-87). A further step that is used to improve the reactivity of [18 F]-fluoride for radiofluorination reactions is to add a cationic counterion prior to the removal of water. Suitably, the counterion should possess sufficient solubility within the anhydrous on solvent to maintain the solubility of the [18 F]-fluoride. Therefore, counterions that are typically used include large but soft metal ions such as rubidium or caesium, potassium complexed with a cryptand such as KryptofixTM , or lkylammonium salts, wherein ium complexed with a cryptand such as Kryptofix TM , or tetraalkylammonium salts are red.

A "precursor nd" comprises a non-radioactive derivative of a radiolabelled compound, designed so that chemical on with a convenient chemical form of the detectable label occurs site-specifically; can be conducted in the minimum number of steps (ideally a single step); and without the need for significant purification (ideally no further purification), to give the desired radiolabelled compound. Such precursor compounds are tic and can conveniently be obtained in good chemical purity.

A suitable "leaving group" in the context of the present ion is a chemical group that can be displaced by nucleophilic displacement on with fluoride ion. These are well-known in the art of synthetic chemistry. In some ments the leaving group of the present invention is a linear or branched C1-10 haloalkyl sulfonic acid substituent, a linear or branched C1-10 alkyl sulfonic acid substituent, a fluorosulfonic acid substituent, or an aromatic sulfonic acid substituent. In other embodiments of the invention the leaving group is ed from methanesulfonic acid, toluenesulfonic acid, nitrobenzenesulfonic acid, benzenesulfonic acid, trifluoromethanesulfonic acid, fluorosulfonic acid, and perfluoroalkylsulfonic acid. In some embodiments the leaving group is either methanesulfonic acid, trifluoromethanesulfonic acid or toluenesulfonic acid and in another embodiment the leaving group is trifluoromethanesulfonic acid.

The term "protecting group" refers to a group which inhibits or sses undesirable al reactions, but which is designed to be sufficiently reactive that it may be cleaved from the functional group in on to obtain the desired product under mild enough conditions that do not modify the rest of the molecule. Protecting groups are well known to those skilled in the art and are described in ‘Protective Groups in Organic Synthesis’, Theorodora W. Greene and Peter G. M. Wuts, (Fourth Edition, John Wiley & Sons, 2007).

The PG1 "carboxy protecting group" is preferably linear or branched C1-10 alkyl chain or an aryl substituent. The term "alkyl" used either alone or as part of another group is defined as any ht, branched or cyclic, saturated or unsaturated CnH2n+1 group. The term "aryl" refers to any C6-14 molecular fragment or group which is derived from a clic or polycyclic aromatic hydrocarbon, or a monocyclic or polycyclic heteroaromatic hydrocarbon. In one embodiment of the method of the ion PG1 is selected from methyl, ethyl, l and phenyl. In another embodiment of the invention PG 1 is methyl or ethyl and in yet another embodiment PG 1 is ethyl.

The PG2 "amine protecting group" suitably prevents reaction between 18 F and the amino group in the process of providing the compound of Formula II. Examples of suitable amine protecting groups e various carbamate tuents, various amide substituents, s imide substituents, and s amine substituents. Preferably, the amine protecting group is selected from the group consisting of linear or branched C2-7 alkyloxycarbonyl substituents, linear or branched C3-7 alkenyloxycarbonyl substituents, C7-12 benzyloxycarbonyl substituents that may have a modifying group, C2-7 alkyldithiooxycarbonyl substituents, linear or branched C1-6 alkylamide substituents, linear or branched C2-6 alkenylamide substituents, C6-11 benzamide substituents that may have a modifying group, C4-10 cyclic imide substituents, C6-11 aromatic imine substituents that may have a substituent, linear or branched C1-6 alkylamine substituents, linear or ed C2-6 alkenylamine substituents, and C6-11 benzylamine substituents that may have a modifying group. In some embodiments of the invention PG2 is selected from t-butoxycarbonyl, allyloxycarbonyl, phthalimide, and N- benzylideneamine. In other embodiments PG2 is selected from t-butoxycarbonyl or imide. In one embodiment of the invention PG2 is t-butoxycarbonyl.

The term "reacting" refers to bringing two or more al substances (typically referred to in the art as ants" or "reagents") together to result in a chemical change in one or both/all of the chemical substances.

A "PG1 deprotecting agent" is a reagent capable of removing the carboxy protecting group PG1 from the compound of a II during the reacting step (b). Suitable such carboxy deprotecting agents are well-known to the skilled person (see Greene and Wuts, supra ) and may be either an acid or an alkaline solution. The concentration of the PG 1 deprotecting agent is not limited as long as it is sufficient to remove the carboxy protecting group PG1 and does not have an effect on the final purity or s in an atibility with any container used. Preferably the PG1 deprotecting agent is an alkaline solution. In certain embodiments the PG1 deprotecting agent is a sodium hydroxide or a potassium hydroxide solution and in a preferred embodiment is a sodium hydroxide solution, for example of 0.5-2.0M. The ng step is enabled by closing the outlet of the SPE column so that the PG1 deprotecting agent is retained therein for a specified amount of time. The temperature and the duration of this reacting step need to be sufficient to permit removal of the PG1 carboxy deprotecting group. In certain ments the reacting step is d out at room ature and for a duration of between 1-5 minutes.

The "PG2 deprotecting agent" is a reagent capable of removing the amine protecting group PG2 from the compound of Formula III during the ng step (e). Suitable such amine deprotecting agents are well-known to the skilled person (see Greene and Wuts, supra ) and may be either an acid or an alkaline solution. The concentration of the PG 2 deprotecting agent is not d as long as it is sufficient to remove the carboxy protecting group PG2. Preferably the PG 2 deprotecting agent is an acid solution. A suitable acid preferably includes an acid selected from inorganic acids such as hydrochloric acid, sulfuric acid and nitric acid, and organic acids such as perfluoroalkyl carboxylic acid, e.g. trifluoroacetic acid. In certain embodiments, the PG2 deprotecting agent is hydrochloric acid, and in other embodiments when HCl is used as PG2 deprotecting agent it is at a concentration of 0M. Reacting step (e) is ably carried out with heat to allow the removal of PG2 reaction to proceed more rapidly. The reaction time depends on the reaction temperature or other conditions. For example, when the reacting step (e) is performed at 60°C, a sufficient reaction time is 5 minutes.

Precursor compounds of Formula I may be obtained by following or adapting methods known in the art, such as for example described by McConathy et al (2003 Appl Radiat ; 58: 657-666) or by Shoup and Goodman (1999 J Label Comp Radiopharm; 42: 215-225).

In a preferred aspect, the [18F]-FACBC is transamino[18F]- fluorocyclobutanecarboxylic acid (anti-[18F]-FACBC): said compound of Formula I is a compound of Formula Ia: (Ia) said compound of Formula II is a compound of Formula IIa: (IIa); and, said compound of Formula III is a compound of Formula IIIa: (IIIa) wherein PG1 and PG2 are as described above.

In some embodiments the method of present ion additionally includes a step following the reacting step and before the formulating step of purifying the reaction e obtained in the reacting step to obtain substantially pure [18F]FACBC.

The term antially" as used in "substantially pure" takes the meaning as presented above. The term "substantially pure" as used in the context of [18 F]FACBC encompasses completely pure [18 C or [18 F]FACBC that is sufficiently pure to be suitable for use as a PET tracer. The term "suitable for use as a PET tracer" means that the [18 F]FACBC product is suitable for intravenous stration to a mammalian subject followed by PET imaging to obtain one or more clinically-useful images of the location and/or distribution of [18 F]-FACBC.

A suitable purifying step comprises: (i) carrying out a first purification step comprising passing said reaction mixture h a hilic lipophilic ed (HLB) solid phase; and, (ii) ally carrying out a second purification step comprising passing said reaction mixture through an alumina solid phase.

In certain embodiments of the present invention said purifying step can be said to consist essentially of the above-defined steps. In particular, the purifying step does not e that the reaction mixture is passed through an ion retardation column. This is a notable distinction over the prior art methods where this is a required step in order to remove ions and to neutralise the reaction mixture (e.g. as described by McConathy et al (2003 Appl Radiat Isotop; 58: 657-666), and in EP20172580029 (A)). As such, the method of the present invention is simplified over the prior art methods and as such is more suitable for automation.

In a preferred ment the method of the invention is carried out on an automated synthesis apparatus. By the term "automated synthesis apparatus" is meant an automated module based on the principle of unit operations as described by Satyamurthy et al (1999 Clin Positr Imag; 2(5): 233-253). The term ‘unit operations" means that x processes are d to a series of simple operations or reactions, which can be applied to a range of materials. Such automated synthesis apparatuses are preferred for the method of the present ion especially when a radiopharmaceutical composition is desired. They are commercially available from a range of suppliers (Satyamurthy et al, above), including: GE Healthcare; CTI Inc; Ion Beam Applications S.A. (Chemin du Cyclotron 3, B-1348 Louvain-La-Neuve, Belgium); Raytest (Germany) and Bioscan (USA).

A commercial automated synthesis apparatus also provides suitable containers for the liquid radioactive waste generated as a result of the radiopharmaceutical preparation.

Automated synthesis apparatuses are not typically provided with radiation shielding, since they are ed to be employed in a suitably configured radioactive work cell. The radioactive work cell es suitable radiation shielding to protect the operator from potential radiation dose, as well as ventilation to remove chemical and/or radioactive s. The automated synthesis apparatus preferably comprises a cassette. By the term "cassette" is meant a piece of apparatus ed to fit removably and interchangeably onto an automated synthesis apparatus, in such a way that mechanical movement of moving parts of the synthesizer controls the ion of the cassette from outside the cassette, i.e. externally. Suitable cassettes comprise a linear array of valves, each linked to a port where reagents or vials can be attached, by either needle puncture of an inverted septum-sealed vial, or by gas-tight, marrying joints. Each valve has a male-female joint which interfaces with a corresponding moving arm of the automated synthesis apparatus. External rotation of the arm thus controls the g or closing of the valve when the cassette is attached to the automated synthesis tus. Additional moving parts of the ted synthesis apparatus are ed to clip onto syringe plunger tips, and thus raise or depress syringe barrels.

The cassette is versatile, typically having l positions where reagents can be attached, and several suitable for attachment of syringe vials of reagents or chromatography cartridges (e.g. for SPE). The cassette always comprises a on . Such reaction vessels are preferably 0.5 to 10 mL, more preferably 0.5 to 5 mL and most preferably 0.5 to 4 mL in volume and are configured such that 3 or more ports of the cassette are connected thereto, to permit transfer of reagents or solvents from s ports on the cassette.

Preferably the cassette has 15 to 40 valves in a linear array, most preferably 20 to 30, with being especially preferred. The valves of the cassette are preferably each identical, and most preferably are 3-way valves. The cassettes are designed to be suitable for radiopharmaceutical manufacture and are therefore manufactured from materials which are of pharmaceutical grade and y also are resistant to radiolysis.

Preferred automated synthesis apparatuses for use with the present invention comprise a disposable or single use cassette which comprises all the reagents, on vessels and apparatus necessary to carry out the preparation of a given batch of luorinated radiopharmaceutical. The cassette means that the automated synthesis apparatus has the ility to be capable of making a variety of different harmaceuticals with minimal risk of cross-contamination, by simply changing the te. The te approach also has the advantages of: simplified set-up hence reduced risk of or error; improved GMP (Good Manufacturing Practice) compliance; multi-tracer capability; rapid change between production runs; pre-run automated diagnostic checking of the cassette and reagents; automated barcode cross-check of chemical reagents vs the synthesis to be carried out; reagent traceability; single-use and hence no risk of contamination, tamper and abuse resistance.

The term "comprising" as used in this specification means "consisting at least in part of".

When interpreting each statement in this ication that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner.

The following example serves to further illustrate the invention.

Brief Description of the es Example 1 describes a method to obtain the composition of the present invention.

List of Abbreviations used in the Examples ATR attenuated total reflectance DTGS deuterated triglycine sulphate [18 F]FACBC 1-amino[18 F]fluorocyclobutanecarboxylic acid FT-IR Fourier transform infrared K222 Kryptofix 222 MeCN acetonitrile MeOH methanol QMA quaternary methyl ammonium RCY radiochemical yield SPE solid-phase extraction TLC thin layer chromatography UV ultraviolet Examples All reagents and solvents were purchased from Merck and used without further purification. The [18 F]FACBC precursor; Syn (N-(tert-butoxycarbonyl)amino) [[(trifluoromethyl)sulfonyl]oxy]-cyclobutanecarboxylic acid ethyl ester was obtained from GE Healthcare. The Oasis HLB plus cartridge and the Sep-Pak cartridges: QMA light Plus (K2CO 3 form), tC18 light, Alumina N light were purchased from Waters (Milford, MA, USA). A Capintec NaI ion chamber was used for all radioactive measurements (model ). Radio-thin layer chromatography (radio-TLC) was performed on a Packard instant imager using ated plates of silica gel (Merck 60F 254 ).

Example 1: Synthesis and Formulation of [18 C Composition of the Invention No-carrier-added [18 F]fluoride was produced via the 18 O(p,n) 18 F nuclear on on a GE ce 6 cyclotron (Norwegian Cyclotron Centre, Oslo). Irradiations were performed using a dual-beam, 30µA current on two equal Ag targets with HAVAR foils using 16.5 MeV protons. Each target ned 1.6 ml of ≥ 96% [18 O]water (Marshall Isotopes). Subsequent to irradiation and delivery to a hotcell, each target was washed with 1.6 ml of [16 O]water (Merck, water for GR analysis), giving imately 2-5 Gbq in 3.2 ml of [16 O]water.

All radiochemistry was performed on a commercially available GE FASTlabTM with a single-use cassette. Each cassette is built around a one-piece-moulded manifold with 25 three-way stopcocks, all made of polypropylene. Briefly, the cassette includes a 5 ml reactor (cyclic olefin copolymer), one 1 ml syringe and two 5 ml syringes, spikes for connection with five prefilled vials, one water bag (100 ml) as well as various SPE cartridges and filters. Fluid paths are controlled with nitrogen purging, vacuum and the three syringes. The fully ted system is designed for single-step fluorinations with cyclotron-produced [18 F]fluoride. The FASTlab was programmed by the software package in a step-by-step time-dependent sequence of events such as moving the syringes, nitrogen purging, vacuum, and ature regulation. Synthesis of [18 F]FACBC followed the three general steps: (a) [18 F]fluorination, (b) hydrolysis of protection groups and (c) SPE purification.

Vial A ned K222 (156 µmol), K2CO 3 (60.8 µmol) in 79.5% (v/v) MeCN(aq) (1105 µl). Vial B contained 4M HCl. Vial C contained MeCN. Vial D contained precursor (123.5 µmol) in its dry form (stored below –5 °C until cassette assembly). Vial E ned 2 M NaOH (4.1 ml). The 30 ml product collection glass vial was filled with 200 mM citrate buffer (10 ml). Aqueous [18 F]fluoride (1-1.5 ml, 100-200 Mbq) was passed through the QMA and into the 18 O-H2O ry vial. The QMA was then flushed with MeCN and sent to waste. The trapped [18 F]fluoride was eluted into the reactor using eluent from vial A (730 µl) and then concentrated to dryness by azeotropic distillation with acetonitrile (80 µl, vial C). Approximately 1.7 ml of MeCN was mixed with precursor in vial D from which 1.0 ml of the dissolved precursor (corresponds to 72.7 mmol precursor) was added to the reactor and heated for 3 min at 85°C. The reaction mixture was diluted with water and sent through the tC18 cartridge. Reactor was washed with water and sent h the tC18 cartridge. The labelled intermediate, fixed on the tC18 cartridge was washed with water, and then incubated with 2M NaOH (2.0 ml) for 5 min. The labelled ediate (without the ester group) was eluted off the tC18 dge into the reactor using water. The BOC group was ysed by adding 4M HCl (1.4 ml) and heating the reactor for 5 min at 60 °C. The reactor t with the crude [18 F]FACBC was sent h the HLB and Alumina cartridges and into the 30 ml product vial. The HLB and Alumina cartridges were washed with water (9.1 ml total) and collected in the product vial. y, 2M NaOH (0.9 ml) and water (2.1 ml) was added to the product vial, giving the purified formulation of [18 F]FACBC with a total volume of 26 ml. Radiochemical purity was measured by radio-TLC using a mixture of MeCN:MeOH:H2O:CH 3COOH (20:5:5:1) as the mobile phase. The radiochemical yield (RCY) was expressed as the amount of radioactivity in the [18 F]FACBC fraction divided by the total used [18 F]fluoride activity (decay ted).

Total synthesis time was 43 min.

Claims (25)

1.Claims

2.(1) A pharmaceutical composition of [18 F]aminofluorocyclobutanecarboxylic

3.acid (18 F-FACBC) wherein said composition ses:

4.(i) 50-100 mM citrate ; and,

5.(ii) has a pH of 4.0-5.0; and

6.(iii) not more than 150 µg/mL 1-aminohydroxyl-cyclobutanecarboxylic

7.acid (hydroxyl-ACBC).

8.(2) The pharmaceutical composition as defined in Claim 1 comprising 60-90 mM

9.citrate buffer.

10.(3) The pharmaceutical composition as defined in either Claim 1 or Claim 2

11.comprising 75-85 mM citrate buffer.

12.(4) The pharmaceutical composition as defined in any one of Claims 1-3 that has a pH

13.of 4.1-4.5.

14.(5) The ceutical composition as defined in any one of Claims 1-4 that has an

15.end of synthesis (EOS) radioactive concentration (RAC) of at least 1000 MBq/mL.

16.(6) The pharmaceutical composition as d in any one of Claims 1-5 that has an

17.end of synthesis (EOS) radioactive tration (RAC) of at least 1500 MBq/ml.

18.(7) The pharmaceutical composition as defined in any one of Claims 1-6 which

19.comprises not more than 150 µg/mL 1-aminohydroxyl-cyclobutanecarboxylic

20.acid (hydroxyl-ACBC).

21.(8) The pharmaceutical composition as defined in any one of Claims 1-7 which

22.comprises not more than 80 µg/mL hydroxyl-ACBC.

23.(9) The pharmaceutical composition as d in any one of Claims 1-8 which

24.comprises not more than 0.15 µg/mL 1-aminofluoro-cyclobutanecarboxylic

25. acid (FACBC). (10) The pharmaceutical composition as defined in any one of Claims 1-9 which comprises not more than 0.10 µg/mL FACBC. (11) The pharmaceutical composition as defined in any one of Claims 1-10 which comprises not more than 2.0 µg/mL 1-aminochloro-cyclobutanecarboxylic acid (chloro-ACBC). 5 (12) The pharmaceutical composition as defined in any one of Claims 1-11 which comprises not more than 1.0 µg/mL chloro-ACBC. (13) The pharmaceutical composition as defined in any one of Claims 1-12 with the proviso that said composition does not se a radiostabiliser. (14) The pharmaceutical ition as defined in Claim 13 wherein said 10 radiostabiliser is a sugar lactone or a sugar alcohol. (15) A method to obtain a radiopharmaceutial composition wherein said composition is as defined in any one of Claims 1-14 and n said method comprises: (i) reacting with a suitable source of [18F]fluoride a precursor compound of Formula I: 15 (I) wherein: LG is a leaving group; PG1 is a carboxy ting group; and, PG2 is an amine protecting group; 20 to obtain a compound of Formula II: (II). wherein PG1 and PG2 are as defined for Formula II; (ii) reacting said compound of Formula II with a PG1 deprotecting agent to obtain a nd of Formula III: (III); 5 n PG2 is as defined for Formula I; (iii) reacting said compound of Formula III with a PG 2 deprotecting agent to obtain ACBC; (iv) formulating said [18F]FACBC with citrate buffer to obtain said pharmaceutical composition. 10 (16) The method as defined in Claim 15 wherein said [18F]-FACBC is transamino [18F]-fluorocyclobutanecarboxylic acid (anti-[18F]-FACBC): said compound of Formula I is a compound of Formula Ia: (Ia). 15 said compound of Formula II is a compound of Formula IIa: (IIa); and, said compound of Formula III is a compound of Formula IIIa: (IIIa) wherein PG1 and PG2 are as defined in Claim 15 for Formula I. 5 (17) The method as defined in either Claim 15 or Claim 16 wherein PG1 is ethyl. (18) The method as defined in any one of Claims 15-17 wherein PG2 is tbutoxycarbonyl. (19) The method as defined in any one of Claims 15-18 wherein said PG1 deprotecting agent is NaOH. 10 (20) The method as defined in any one of Claims 15-19 wherein said PG2 deprotecting agent is HCl. (21) The method as defined in any one of Claims 15-20 which is d out on an automated synthesis apparatus. (22) A harmaceutical composition when produced by a method of any one of 15 claims 15 to 21. (23) A pharmaceutical composition as claimed in any one of claims 1 to 14, substantially as herein described with reference to any e thereof. (24) A method as claimed in any one of claims 15 to 21 of obtaining a radiopharmaceutical composition, substantially as herein described with reference to any example thereof. (25) A harmaceutical composition as claimed in claim 22, substantially as herein described with reference to any example thereof.